We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 06, 2021

Imatinib as an Adjuvant in Localized Gastrointestinal Stromal Tumors

Annals of Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
Final Analysis of the Randomized Trial on Imatinib as an Adjuvant in Localized Gastrointestinal Stromal Tumors (GIST) From the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)
Ann. Oncol 2021 Jan 19;[EPub Ahead of Print], PG Casali, A Le Cesne, AP Velasco, D Kotasek, P Rutkowski, P Hohenberger, E Fumagalli, IR Judson, A Italiano, H Gelderblom, N Penel, HG Kopp, F Duffaud, D Goldstein, JM Broto, A Gronchi, E Wardelmann, S Marréaud, JR Zalcberg, S Litière, JY Blay

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading